» Articles » PMID: 33950354

Whole Genomic DNA Methylation Profiling of CpG Sites in Promoter Regions of Dorsal Root Ganglion in Diabetic Neuropathic Pain Mice

Overview
Journal J Mol Neurosci
Date 2021 May 5
PMID 33950354
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

DNA methylation and demethylation play an important role in neuropathic pain. In general, DNA methylation of CpG sites in the promoter region impedes gene expression, whereas DNA demethylation contributes to gene expression. Here, we evaluated the methylation status of CpG sites in genomic DNA promoter regions in dorsal root ganglions (DRGs) of diabetic neuropathic pain (DNP) mice. In our research, streptozotocin (STZ) was intraperitoneally injected into mice to construct DNP models. The DNP mice showed higher fasting blood glucose (above 11.1 mmol/L), lower body weight, and mechanical allodynia than control mice. Whole-genome bisulfite sequencing (WGBS) revealed an altered methylation pattern in CpG sites in the DNA promoter regions in DRGs of DNP mice. The results showed 376 promoter regions with hypermethylated CpG sites and 336 promoter regions with hypomethylated CpG sites. In addition, our data indicated that altered DNA methylation occurs primarily on CpG sites in DNA promoter regions. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed that differentially methylated CpG sites annotated genes were involved in activities of the nervous and sensory systems. Enrichment analysis indicated that genes in these pathways contributed to diabetes or pain. In conclusion, our study enriched the role of DNA methylation in DNP.

Citing Articles

Epigenetic modifications associated to diabetic peripheral neuropathic pain (Review).

Gao T, Luo J, Fan J, Gong G, Yang H Mol Med Rep. 2024; 31(1).

PMID: 39540354 PMC: 11579833. DOI: 10.3892/mmr.2024.13394.


Pathology of pain and its implications for therapeutic interventions.

Cao B, Xu Q, Shi Y, Zhao R, Li H, Zheng J Signal Transduct Target Ther. 2024; 9(1):155.

PMID: 38851750 PMC: 11162504. DOI: 10.1038/s41392-024-01845-w.


The Epigenetics of Neuropathic Pain: A Systematic Update.

Petho G, Kantas B, Horvath A, Pinter E Int J Mol Sci. 2023; 24(24).

PMID: 38138971 PMC: 10743356. DOI: 10.3390/ijms242417143.


The upregulation of NLRP3 inflammasome in dorsal root ganglion by ten-eleven translocation methylcytosine dioxygenase 2 (TET2) contributed to diabetic neuropathic pain in mice.

Chen W, Wang X, Sun Q, Zhang Y, Liu J, Hu T J Neuroinflammation. 2022; 19(1):302.

PMID: 36527131 PMC: 9756585. DOI: 10.1186/s12974-022-02669-7.

References
1.
Chaplan S, Bach F, Pogrel J, Chung J, Yaksh T . Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994; 53(1):55-63. DOI: 10.1016/0165-0270(94)90144-9. View

2.
Cheng C, Kobayashi M, Martinez J, Ng H, Moser J, Wang X . Evidence for Epigenetic Regulation of Gene Expression and Function in Chronic Experimental Diabetic Neuropathy. J Neuropathol Exp Neurol. 2015; 74(8):804-17. DOI: 10.1097/NEN.0000000000000219. View

3.
Chidambaran V, Zhang X, Martin L, Ding L, Weirauch M, Geisler K . DNA methylation at the mu-1 opioid receptor gene () promoter predicts preoperative, acute, and chronic postsurgical pain after spine fusion. Pharmgenomics Pers Med. 2017; 10:157-168. PMC: 5432115. DOI: 10.2147/PGPM.S132691. View

4.
Ciccacci C, Latini A, Colantuono A, Politi C, DAmato C, Greco C . Expression study of candidate miRNAs and evaluation of their potential use as biomarkers of diabetic neuropathy. Epigenomics. 2020; 12(7):575-585. DOI: 10.2217/epi-2019-0242. View

5.
Ehrlich M . DNA hypermethylation in disease: mechanisms and clinical relevance. Epigenetics. 2019; 14(12):1141-1163. PMC: 6791695. DOI: 10.1080/15592294.2019.1638701. View